A total of 30 mice were divided into three treatment groups in an experiment using the mouse colorectal cancer model CT26: untreated, anti-PD-1 antibody monotherapy, or anti-PD-1 and anti-CTLA-4 antibody combination (DICB). The gene discussed is CTLA4; the disease is colorectal cancer.